Storyline: Danish drugmaker Novo Nordisk eyes growth in China [Voice_over] Meeting with Ren Hongbin, the chairman of the China Council for the Promotion of International Trade, Novo Nordisk's chairman Helge Lund expressed optimism about China - already one of its fastest-growing markets. The Danish pharmaceutical is a key player in diabetes care here, and in 2024 launched its blockbuster weight-loss drug, Wegovy. [Sound_bite] Helge Lund, Chair of the Board of Directors, Novo Nordisk: "We believe that around 150 million people have diabetes, and around 180 million people in China have obesity. And of course, for a company like Novo, that comes with opportunities, but also with big responsibilities." [Voice_over] Now entering its third decade in the Chinese market, the company is aligning with Healthy China 2030 - a government-led initiative with ambitious targets for preventing and managing chronic diseases. [Sound_bite] Helge Lund, Chair of the Board of Directors, Novo Nordisk: "We really applaud the strong objectives, the clear targets, the good plans, and the actions that the Chinese government is taking to deal with chronic diseases, such as the healthy initiative 2030 that the government is leading. And we would like to be a forward-looking, innovative, and long-trusted partner for the Chinese government in dealing with these and other challenges in the healthcare space." [Voice_over] China is one of Novo Nordisk's fastest-growing markets. In the first half of 2025, the company reported revenues of around 23 billion US dollars worldwide, with China contributing nearly one billion, up six percent. [Restrictions : No access Chinese mainland]